Lung ultrasound response to awake prone positioning predicts the need for intubation in patients with COVID-19 induced acute hypoxemic respiratory failure: an observational study

Background: Awake prone positioning (APP) reduces the intubation rate in COVID-19 patients treated by high-flow nasal cannula (HFNC). However, the lung aeration response to APP has not been addressed. We aimed to explore the lung aeration response to APP by lung ultrasound (LUS). Methods: This two-c...

ver descrição completa

Detalhes bibliográficos
Autores: Ibarra-Estrada, M, Gamero-Rodriguez, MJ, Garcia-de-Acilu, M, Roca, O, Sandoval-Plascencia, L, Aguirre-Avalos, G, Garcia-Salcido, R, Aguirre-Diaz, SA, Vines, DL, Mirza, S, Kaur, R, Weiss, T, Guerin, C, Li, J
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1315
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/1315
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132955504&doi=10.1186%2fs13054-022-04064-3&partnerID=40&md5=36bba8852f6adda038af7246a10aa775
Access Level:acceso abierto
Palavra-chave:COVID-19
Awake prone positioning
Lung ultrasound
High-flow nasal cannula
Intubation
Descrição
Resumo:Background: Awake prone positioning (APP) reduces the intubation rate in COVID-19 patients treated by high-flow nasal cannula (HFNC). However, the lung aeration response to APP has not been addressed. We aimed to explore the lung aeration response to APP by lung ultrasound (LUS). Methods: This two-center, prospective, observational study enrolled patients with COVID-19-induced acute hypoxemic respiratory failure treated by HFNC and APR LUS score was recorded 5-10 min before, 1 h after APP, and 5-10 min after supine in the first APP session within the first three days. The primary outcome was LUS score changes in the first three days. Secondary outcomes included changes in SpO(2)/FiO(2) ratio, respiratory rate and ROX index (SpO(2)/FiO(2)/respiratory rate) related to APP, and the rate of treatment success (patients who avoided intubation). Results: Seventy-one patients were enrolled. LUS score decreased from 20 (interquartile range [IQR] 19-24) to 19 (18-21) (p < 0.001) after the first APP session, and to 19 (18-21) (p < 0.001) after three days. Compared to patients with treatment failure (n = 20, 28%), LUS score reduction after the first three days in patients with treatment success (n = 51) was greater (-2.6 [95% confidence intervals-3.1 to - 2.0] vs 0 [- 1.2 to 1.2], p = 0.001). A decrease in dorsal LUS score > 1 after the first APP session was associated with decreased risk for intubation (Relative risk 0.25 [0.09-0.69]). APP daily duration was correlated with LUS score reduction in patients with treatment success, especially in dorsal lung zones (r = - 0.76; p < 0.001). Conclusions: In patients with acute hypoxemic respiratory failure due to COVID-19 and treated by HFNC, APP reduced LUS score. The reduction in dorsal LUS scores after APP was associated with treatment success. The longer duration on APP was correlated with greater lung aeration.